BIOMAT Database Logo BIOMAT Database Logo

p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. 1997

E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Department of Pathology, School of Medicine, University of Crete, University General Hospital of Heraklion, Greece.

The aim was to investigate the pattern of expression of p53 protein and two wild-type (wt) p53-induced proteins (mdm2 and p21/waf1), as an indirect way of assessing p53 gene status in breast carcinomas. Formalin-fixed paraffin embedded tissue from 102 cases of breast carcinomas comprising mostly ductal carcinomas (88 cases) was stained by immunohistochemistry for p53, mdm2 and p21/waf1 proteins. We found p53, mdm2 and waf1/p21 protein expression in 33/102, 20/102 and 38/102 breast carcinomas, respectively. Parallel p53/mdm2 protein expression was found in 9 cases. Five were also p21/waf1 positive. Discordant p53+/ mdm2-protein expression was found in 24 cases. Nine were p21/waf1 positive and the remaining fifteen were p21/waf1 negative. The patterns mdm2+/p53-/p21- and p21+/p53-(+)/mdm2- were found in 6 and 20 cases, respectively. Parallel p53/mdm2/p21 protein expression may represent breast carcinomas with wt p53 gene since mdm2 and p21 proteins are inducible by wt p53 gene. In these cases p53 protein expression may be due to stabilisation to mdm2 protein. This could be important in the pathogenesis of these cases since mdm2 may deregulate the p53-dependent growth suppressive pathway. Discordant p53+/mdm2-/p21- protein expression may represent breast carcinomas with p53 gene mutations unable to activate expression of mdm2 and p21 proteins. Breast carcinomas with p53+/mdm2/p21+ protein expression may have either wt p53 with deregulated mdm2 gene expression or mutated p53 gene with p53-independent p21 expression. Cases with only mdm2 expression may represent tumours with mdm2 gene amplification or overexpression and cases with only p21 expression may reflect p53-independent regulation of p21 protein.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016158 Genes, p53 Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53. Genes, TP53,TP53 Genes,p53 Genes,Gene, TP53,Gene, p53,TP53 Gene,p53 Gene
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
p53 protein expression in non-Hodgkin's lymphoma. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
October 1996, Clinical molecular pathology,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53.
September 1997, International journal of cancer,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas.
June 1997, Histopathology,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
January 1998, Anticancer research,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
January 1998, Anticancer research,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
p21(Waf1/Cip1) and p53 protein expression in breast cancer.
June 1997, American journal of clinical pathology,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
January 1997, Anticancer research,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression.
January 1997, Anticancer research,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
Expression of p21/waf1 in oral squamous cell carcinomas--correlation with p53 and mdm2 and cellular proliferation index.
January 1999, Oral oncology,
E Giannikaki, and C Kouvidou, and M Tzardi, and K Stefanaki, and K Koutsoubi, and M Gregoriou, and E Zois, and S Kakolyris, and C Mavroudi, and G Delides, and V Georgoulias, and P Kanavaros
p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis.
December 1999, The Journal of pathology,
Copied contents to your clipboard!